Bispecific Antibodies Catching Fire

10:00 AM - 10:55 AM, Thursday, June 11, 2020 ・ Track Atlantic
Search General Info
Search Education
Search Partnering Companies
Since the first FDA approved bispecific antibody Blincyto hit the market in 2015, a wave of new bispecific technology platforms has emerged with promises to improve upon early generation approaches aimed at engaging two different drug targets with a single monoclonal antibody. Over the past year, a slew of data has emerged showcasing the fruits of this labor, with a range of different types of bispecifics – from T-cell engagers to IO modulators – targeting a multitude of disease indications in and out of oncology. With claims of simpler and more predictable manufacturing compared to the CAR-T immunotherapies and improvements in dose and administration compared to early generation bispecific modalities, 2020 promises to be a big year for bispecific antibodies. Companies on the crest of this wave detail their predictions on the emergence of bispecific antibodies, and their potential to open up new biology in cancer and other diseases.
Moderator
photo
Analyst
Canaccord Genuity
Speakers
photo
SVP, Discovery Biotherapeutics
Bristol Myers Squibb
photo
Shriram Chair of the Department of Bioengineering at Stanford University
Stanford University
photo
President and Chief Executive Officer
Xencor
photo
Co-founder and Chief Executive Officer
Compass Therapeutics